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3Running head: Meta-Analysis of metastatic uveal melanoma trials
Abstract 
Background: Despite the completion of numerous phase II studies, a standard of care 
treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine 
benchmarks of progression free survival (PFS) and overall survival (OS), we 
performed a meta-analysis using individual patient level trial data.
METHODS: Individual patient variables and survival outcomes were requested from 
29 trials published from 2000-2016. Univariable and multivariable analysis were 
performed for prognostic factors. The variability between trial arms and between 
therapeutic agents on PFS and OS was investigated.
RESULTS: OS data were available for 912 patients. The median PFS was 3.3 months 
(95%CI 2.9 to 3.6) and 6-month PFS rate was 27% (95% CI 24 to 30).  Univariable 
analysis showed male sex, elevated (i.e. > vs ≤ upper limit of normal (ULN)) lactate 
dehydrogenase (LDH), elevated alkaline phosphatase (ALP) and diameter of the 
largest liver metastasis (≥3cm vs <3cm) to be significantly associated with shorter 
PFS. Multivariable analysis showed male sex, elevated LDH, and elevated ALP were 
significantly associated with shorter PFS. The most significant factors associated with 
6-month PFS rate, on both univariable and multivariable analysis were elevated LDH 
and ALP. The median OS was 10.2 months (95% CI 9.5 to 11.0) and 1 year OS was 
43% (95% CI 40 to 47). The most significant prognostic factors for shorter OS by 
univariable and multivariable analysis were elevated LDH and elevated ALP. Patients 
treated with liver directed treatments had statistically significant longer PFS and OS.
CONCLUSION: Benchmarks of 6-month PFS and 1-year OS rates were determined 
accounting for prognostic factors. These may be used to facilitate future trial design 
and stratification in mUM. 
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4Abstract: 271 words
Body:  3070 words
Key words: meta-analysis, uveal melanoma, trial design, survival benchmarks
Key message: A meta-analysis of early phase trials in metastatic uveal melanoma 
to establish survival benchmarks for future trial design. Prognostic factors are also 
defined for stratification purposes.
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5Introduction
Uveal melanoma is the most common intraocular tumor in adults and accounts for 3% 
of all melanomas[1]. Whereas treatment for the primary melanoma is successful in the 
majority of cases, metastatic relapse occurs in approximately 30% of patients[2-4]. 
Assays using a variety of techniques have the ability to analyse the primary tumor to 
predict ultimate progression free (PFS) and overall survival (OS) [5-10]. However to 
date, there are no prognostic models in newly diagnosed metastatic disease in clinical 
use and reported OS estimates remain in the range of 3 to 12 months in unselected 
populations[11]. 
Further, there is no standard of care treatment in the metastatic setting where 
dacarbazine remains a standard control arm in contemporary studies despite limited 
activity[12-14]. Systemic treatment with a variety of agents has been tested in a 
multitude of phase I-II studies examining anti-angiogenics, kinase inhibitors, 
chemotherapies, and immunotherapy[11, 15]. These studies have been relatively 
small and, although some have reported encouraging response rates with 
heterogeneous survival outcomes, none have resulted in a successful practice 
changing phase III trial. Indeed, it has been challenging to discern the relative 
significance of results from early phase non-randomized trials, due to lack of standard-
of-care therapies and established benchmarks for comparison. Understanding 
prognostic factors and benchmarks for metastatic uveal melanoma will ultimately 
facilitate rational trial design to target appropriate subgroups given the heterogeneity 
of disease outcomes. For example, unlike other cancers, a common therapeutic 
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6modality is liver directed therapy as >80% of patients initially relapse with liver 
metastases [1, 16]. However data to support improved survival outcomes with this 
modality are sparse[11, 15]. Surgical resection may result in long term survival 
outcomes for a few but is not feasible in the majority due to extent of disease[17]. 
Given these considerations[18], we set out to perform a meta-analysis of phase Ib/III 
trials in metastatic uveal melanoma using patient level data to address critical clinical 
questions.
Methods
Aims of the study
The primary aims were to 1) To estimate PFS and OS benchmarks to facilitate 
planning of future clinical trials, 2) To identify prognostic markers which could serve as 
stratification variables in future trials and 3) To explore whether different classes of 
treatment are associated with differential outcomes. 
Study selection and individual patient level data 
Trials were identified from a literature search and reviewed independently by 2 
investigators (LK, AJ). The literature search was conducted using PubMed, 
www.clinicaltrials.gov, the American Society of Clinical Oncology website (for 
congress abstracts), Cochrane register of controlled trials and European Society of 
Medical Oncology (ESMO) meeting abstracts. Studies were restricted to those 
published between January 1988 and January 2015 and with a minimum of 10 patients 
prospectively enrolled using a therapy for metastatic disease (either systemic or loco-
regional which could be given as any line of treatment). Individual investigators were 
then approached by a steering committee (AJ, LK, SS, SP, RC) to contribute data of 
all patients treated on protocol. The flow of information through the phases of the 
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7review process (of the literature search results) according to the PRISMA 
statement[19] are shown in supplementary figure 1. 
Individual patient variables at baseline were requested, including age, sex, ECOG 
performance status, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), time 
from diagnosis of metastatic disease to start of treatment, treatment received, number 
of cycles of treatment, line of treatment, number of liver metastases (≥10 or <10), 
percentage involvement of the liver (>50% or ≤50%), diameter (cm) of the largest liver 
metastasis, presence of extra-hepatic liver involvement, the response criteria used in 
the trial, as well as the best response achieved and date of best response, date of 
progression or last disease evaluation, date of death or last known to be alive. PFS 
was measured from the date of first treatment to the date of progression or death (or 
censoring). OS was measured from the date of first treatment to death (or censoring). 
This meta-analysis was registered in http://www.crd.york.ac.uk/PROSPERO 
(registration number CRD42014006965) and approved by the University Health 
Network research ethics board (13-7182-CE).
Statistical Analysis
Categorical variables of sex, ECOG status, LDH and ALP (> vs ≤ ULN), and presence 
or absence of extrahepatic metastases were summarized with counts and 
percentages.  Continuous variables such as LDH and ALP were dichotomized and 
presented as categorical variables.  Variable age was summarized as median with 
range, and was categorized (≥65 vs < 65 years). Within the limits of the data available, 
the possible prognostic value of all patient characteristics was assessed, including the 
year the study was published (analysed as a binary covariate (2003-2005 vs 2006-
2015). 
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8The following variables were considered in the assessment of prognostic value in 
univariate and multivariable analysis: ECOG, age (≥65 vs <65 years), sex, LDH and  
ALP level, diameter of the largest liver metastasis (<3cm vs ≥3cm) and site of 
metastases (hepatic vs non hepatic vs both). Binary partitioning techniques were used 
to obtain the optimum cut-off for the continuous variable of age (65 years). A cut off 
for the diameter of the largest liver metastasis of 3 cm was used, aligned with the 
American Joint Committee on cancer (AJCC) substaging of metastatic uveal 
melanoma[20] and allowed for appropriate patient numbers in each group (<3cm 
(n=232) vs ≥3cm (n=365), n=315 were missing) for statistical analysis. Other factors 
relating to liver involvement such as percentage liver involvement were not included 
in the model as such variables were highly correlated with the diameter of the largest 
liver metastasis. Factors identified as significant or of interest in univariate analysis 
were then assessed in the multivariable setting. In order to account for missing values 
in the categorical covariates of interest we included an additional “unknown” category 
to prevent loss of power in testing the remaining non-missing covariates of interest. 
Kaplan-Meier product-limit method was used to estimate time-to-event endpoint (PFS 
and OS) distributions, from which, medians and rates at pre-specified time points (6-
month PFS and 1-year OS rates) were obtained. Cox proportional hazards modelling, 
using sandwich estimator of variance to account for the collinearity of patients within 
studies, was used to assess the prognostic importance of different variables (except 
treatment modalities) both at univariate and multivariable level, based on analyses 
stratified by treatment modalities. Proportional hazards assumption on each of the 
prognostic factors was also assessed graphically by using plots of log of minus log 
survival probability by log of time to event. Generalized linear mixed models (PROC 
GLIMMIX with logit link), that account for the collinearity among patients in the same 
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9study, were used to assess the impact of each of the potential prognostic factors to 
the binary events (6-month PFS rate and 1-year OS rate). Exploration of between trial-
arm variability in event rates was performed comparing event rate of each of the 
treatment arms with the overall event rate, and whether the trial-arm event rate lies 
within 95% confidence interval (CI) of the overall mean based on sample size from 
each trial-arm and by examining for outliers.
We performed sample size calculations for future phase II trials, aiming to improve the 
6-month PFS and/or 1-year OS rates observed in our pooled data [21-26]. Power and 
sample size were computed using binomial enumeration of all possible outcomes.
All tests were two-tailed, with a probability of <0.05 considered statistically 
significance. Statistical analyses were performed using version 9.4 of the SAS System 
for Windows (SAS Institute, Cary, NC) and the open source statistical software R 
version 3.3.1 R Core Team, (R Foundation for Statistical Computing, Vienna, Austria) 
(available at http://www.r-project.org/). 
Results
A total of 38 prospective studies were identified and data were obtained from 29 (76%). 
Reasons for data not being available included a lack of investigator response to 
requests for data and archived data that were no longer available. Of the 29 studies 
for which data were available, 5 involved immunotherapy[27-31], 7 involved a kinase 
inhibitor (of which 2 were randomised studies against temozolomide or dacarbazine 
respectively)[12, 32-36], 2 used an anti-angiogenic agent[37, 38], 8 involved 
chemotherapy (1 of which was a randomized study of intrahepatic vs intravenous 
chemotherapy)[39-45] and 7 studies involved intrahepatic treatment (chemotherapy or 
immunotherapy)[46-52] (supplementary table 1).  
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Data were available for a total of 965 patients.  Response data were available for 793 
(82%), whilst PFS data were available for 881 (91%) patients, of whom 840 (95%) had 
progressed or died and 41 (5%) patients were censored. OS data were available for 
912 (95%), of whom 817 (90%) had died and 95 (10%) patients were alive. There was 
both PFS and OS data for 873 (90% of n=965) patients. Therefore, the maximum data 
available for analysis was for 912 patients, of which 873 were used for PFS analysis.  
Patient characteristics were reflective of contemporary practice (Table 1). A small 
number of observations that were censored before the relevant time point (6  months 
for PFS and 1 year for OS) were omitted from analysis of 6-month PFS rate and 1-
year OS rate: 21 (2.4%) and 28 (3%) of patients respectively.  
Determining benchmarks of survival for PFS and OS
We analysed the complete dataset (n=912 for OS and n=873 for PFS with matching 
OS data available) to define historical benchmarks of OS and PFS. The median PFS 
was 3.3 months (95% CI 2.9 - 3.6). The 6-month PFS rate was 27% (95% CI 24 –30); 
figure 1A. The median OS was 10.2 months (95% CI 9.5 – 11.0). The 1-year OS rate 
was 43% (95% CI 40 – 47); figure 1B.
Prognostic variables for PFS
Univariate analysis showed that male sex, elevated LDH, elevated ALP and larger 
diameter of the largest liver metastasis (≥3cm vs. <3cm) were associated with shorter 
PFS (figure 2A-G). Multivariable analysis revealed that the same variables except 
larger diameter of the largest liver metastasis (≥3cm vs. <3cm) were associated with 
shorter PFS. Elevated LDH and elevated ALP were significant factors by multivariable 
analysis for inferior 6-month PFS rates (table 2). 
Prognostic variables for OS 
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Prognostic features for shorter OS by both univariate and multivariable analysis 
included higher ECOG (≥1 vs 0), male sex, elevated LDH, elevated ALP and larger 
diameter of the largest liver metastasis (≥3cm vs <3cm vs). Higher age (>65 vs <65), 
male sex, elevated LDH, elevated ALP were significant by multivariable analysis for 1-
year OS (table 3 and figure 3A-G). 
Of note, the year the study was published was not significant for PFS or OS. For all 
prognostic factors, the proportional hazards assumption appeared not violated (data 
not shown). 
Survival outcomes between treatment groups and trial arm variability in 6-month 
PFS and 1-year OS 
Recognising that the time of radiological assessment of disease varied between 
studies limiting the accuracy and utility of analysis, we performed an exploratory 
summary of PFS and OS according to treatment groups. The median PFS for each 
treatment group was: immunotherapy 2.8 months (95% CI 2.7-3.1), kinase 2.8 months 
(95% CI 2.7-3.5), anti-angiogenic 2.8 months (95% CI 2.6-5.4), chemotherapy 2.6 
months (95% CI 2.3-3.0) and liver directed therapy 5.2 months (95% CI 4.3-5.9) 
respectively. The median OS for each treatment group was: immunotherapy 8.9 
months (95% CI 7.0-11.6), kinase 9.1 months (95% CI 7.0-10.4), anti-angiogenic 11.0 
months (95% CI 8.2-15.2), chemotherapy 9.2 months (95% CI 8.4-10.4) and liver 
directed therapy 14.6 months (95% CI 12.6-17.5) respectively, figure 4A-B. As an 
exploratory analysis each treatment group was analysed individually (supplementary 
figure 2A-B) and the 6-month PFS rates and the 1-year OS rates for treatment group 
plotted against group sample size. This suggested that only the liver directed treatment 
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arms had a numerically different rate to other treatment modality arms (77% vs 26% 
for overall 6-month PFS) and 88% vs 42.5% for overall 1-year OS.  
Patient characteristics per treatment group were determined (supplementary table 2) 
and the difference in prognostic factors explored firstly between medical treatment 
modalities and secondly between medical (all grouped together) and liver directed 
therapies. ALP and the diameter of the largest liver metastasis differed between trials 
grouped according to medical treatment modality. When comparing medical to liver 
directed treatment, gender, age and diameter of the largest liver lesion differed 
between these two groupings (supplementary table 3). In order to examine the effect 
of treatment modality when controlling for prognostic factors on PFS and OS, we 
performed a multivariable analysis including treatment modality (liver directed vs 
medical treatment) which suggested that liver directed treatment was prognostic for 
PFS and OS (Supplementary Tables 4 and 5 respectively).
Determining separate benchmarks of survival for PFS and OS for medical and 
liver directed therapy
Given the differences in survival and the prognostic benefit of liver directed treatment 
described above we additionally explored separate benchmarks for medical directed 
therapy and liver directed therapy. For medical treatment the median PFS was 2.8 
months (95% CI 2.7 - 2.9), 6-month PFS rate was 21.5% (95% CI 18.4 - 24.8), figure 
5A.  The median OS was 9.3 months (95% CI 8.4 - 10.1). The 1-year OS rate was 
38.4% (95% CI 34.7 - 42.1), figure 5B. For liver directed therapy the median PFS was 
5.2 months (95% CI 4.3-5.9), the 6-month PFS rate was 43.3% (95% CI 36.7 - 49.9); 
figure 5C). The median OS was 14.6 months (95% CI 12.6-17.5). The 1-year OS rate 
was 57.2% (95% CI 50.5 - 63.3); figure 5D).
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Discussion 
We aimed to establish benchmarks of survival and prognostic factors to guide patient 
care and future trial design. The survival outcomes we used (6-month PFS and 1-year 
OS rates) are in line with a previous analysis of cutaneous melanoma[18] , and have 
added relevance in the era of immunotherapeutics where traditional RECIST response 
rates may imprecisely correlate with OS[53]. 
Several prognostic factors for overall survival in metastatic uveal melanoma 
patients have been proposed from previous studies [54-56]. Here we sought to 
validate and build upon these in patients participating in clinical trials. Heterogeneity 
or interactions of factors may imply that many overlap in their prognostic significance 
and further study will better define the significance of factors and optimal cut off values. 
For example, the diameter of the largest liver lesion and the percentage liver 
involvement are both utilised, but both measure tumor bulk. 
The difference in outcomes in the different treatment groups is intriguing. It 
appears that patients selected for liver directed treatment have better survival. They 
may be earlier in the disease trajectory, but we could not evaluate line of therapy as a 
factor due to these data being variably defined in each trial, or their improved survival 
may reflect a more indolent disease due to biological factors or surveillance imaging.  
Moreover, a recent analysis suggested that performance status, LDH and diameter of 
the largest liver metastasis at baseline may not efficiently predict prognosis if liver 
surgery is part of the treatment[56]. Increasing disease burden in the liver appeared 
to be associated with increased disease elsewhere but we were unable to determine 
if the site of first metastases was significant as previously reported[57] nor if time from 
diagnosis of primary tumor or metastatic disease to start of treatment correlated with 
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increased disease burden (the data were not obtainable or largely missing in our 
dataset). 
Importantly, the survival curves that we have generated could serve to 
determine if a new treatment is worthy of further study and may facilitate the 
conduction of standard or adaptively designed trials with appropriately informed 
benchmarks to lead to quicker registration of therapeutic agents. Our study emulates 
the Korn meta-analysis of phase II trials in cutaneous melanoma published in 
2008[18]. Benchmarks of PFS and OS were established in that study using patient 
level data from 42 phase II trials and established criteria to support registrational 
indications. We anticipate these data may have similar utility in the future. The survival 
curves calculated using our data could be used as the comparator to new trial data 
and further study warranted if a specific significance criteria is met[18]. Alternatively, 
the observed PFS or OS rate from our analysis may be used to calculate adequate 
power and sample size for a prospective trial (supplementary data and tables 6-8). 
Using our data as a whole, 49 patients would be required to test in order to detect 
whether a new treatment increases the 6-month PFS rate by 20% (from the current 
27% to 47%), at an alpha error of 5% and a power of 80%; if 19 patients have a PFS 
>6 months then the new treatment should be investigated further. Similarly 56 patients 
would be needed to test if the 1-year OS rate is increased by 20% (from the current 
43% to 63%) at 90% power; if 31 patients have an OS>1 year then further trial of this 
treatment is warranted. The benchmarks for systemic therapy or liver directed therapy 
could be similarly utilised (supplementary tables 7-8)
Whilst informative, our study has limitations: (i) patients included in this analysis 
were fit for clinical trials, generally ECOG 0-1 with preserved organ function (ii) whilst 
all trials were performed prospectively the data used in our analysis was obtained from 
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prospectively collected records or collected retrospectively and in some cases the 
completeness of the data (not all data fields were collected by all investigators) limited 
the analysis and (iii) we produced population wide benchmarks and subgroups 
benchmarks according to therapy. The inclusion of liver directed therapies in an overall 
benchmark analysis, could increase heterogeneity of the study population given that 
these treatments are given in cases of isolated liver disease and are not consistent 
with the systemic nature of the other treatments. However, many patients with liver 
only disease still receive systemic therapies.
Our analysis needs refinement, as our datasets enlarge, to simplify and improve 
the accuracy and utility of the prognostic factors. We were limited in our ability to 
explore the effect of liver tumour bulk on prognosis and the effect of subsequent 
treatments post trial participation on survival was also unknown as we did not have 
access to this data. Lastly the ability to define a population suitable for liver only 
directed treatment will lead to distinct treatment paradigms and require different 
survival benchmarks for trial design, a possibility we explore here but one that requires 
further work.
In conclusion, our meta-analysis indicates that PFS and OS from metastatic 
uveal melanoma remain poor in clinical trials published over the last 13 years. The 
benchmarks and analyses provided here may guide future trial design in metastatic 
uveal melanoma patients where a standard of care is yet to be defined. In light of our 
analysis, we encourage investigators globally to continue to collaborate to improve the 
staging, prognostication and care of patients with metastatic uveal melanoma.
Sources of funding: There was no funding source for this study.
Declaration of interests: all authors declare no competing interests.”
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Figure legends
Figure 1
Kaplan-Meier curves and 95% confidence intervals, for the whole dataset, regarding 
A) Progression free survival and B) Overall survival
Figure 2  
Kaplan-Meier curves for progression free survival from start of treatment according to: 
A) ECOG, B) Age, C) Sex, D) LDH, E) ALP, F) Diameter of the largest liver metastasis 
G) Site(s) of metastases 
Figure 3 
Kaplan-Meier curves for overall survival according to: A) ECOG, B) Age, C) Sex, D) 
LDH, E) ALP, F) Diameter of the largest liver metastasis, G) Site(s) of metastases
Figure 4
Kaplan-Meier curves according to treatment modality received, regarding A) 
Progression free survival and B) Overall survival
Figure 5  
Kaplan-Meier curves and 95% confidence intervals for medical treatment alone, 
regarding A) Progression free survival and B) Overall survival and for liver directed 
therapy alone, regarding C) Progression free survival and D) Overall survival.
Supplementary Figure 1-online
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Flow of information through the phases of review process (of the literature search 
results) according to the PRISMA statement. The literature search was conducted 
using PubMed, www.clinicaltrials.gov, the American Society of Clinical Oncology 
website (for congress abstracts), Cochrane register of controlled trials and European 
society of medical oncology (ESMO) meeting abstracts. Studies were restricted to 
those published between 1988 and Jan 2016 and with a minimum of 10 patients 
prospectively enrolled using a therapy in metastatic disease (either systemic or loco-
regional which could be given as any line of treatment).
Supplementary Figure 2-online
The outcomes for each trial arm compared to the sample size for each of the trial arms 
for A) Progression free survival (PFS) at 6 months and B) Overall survival (OS) at 1 
year. Each trial is colour coded according to treatment modality evaluated; 
immunotherapy (blue), kinases (black), anti-angiogenic agents (green), chemotherapy 
(brown) or liver directed therapy (red)
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1Table 1 Characteristics of patients (data from n=912)
Characteristic Categories Number (%) 
(N=912)
Sex Male
Female
475 (52) 
437 (48)
Age, years (median 61, 
range 18-90)
<65
≥65
Missing
550 (60) 
335 (37)
27 (3)
ECOG/ performance 
status
0
1
2-3
missing 
475 (52)
229 (25)
21 (2)
187 (21) 
LDH Normal 
Elevated (greater than ULN)
Missing
330 (36)
386 (42)
196 (22)
ALP Normal
Elevated (greater than ULN)
Missing
428 (47)
162 (18)
322 (35)
Site of metastases Hepatic alone
Hepatic and extra-hepatic
Extra-hepatic alone
Missing 
473 (52)
234 (26)
92 (10)
113 (12)
Diameter of largest liver 
metastasis (cm)
<3 
≥3
missing
232 (25)
365 (40)
315 (35)
Therapy received Immunotherapy
Anti-angiogenic agents
Kinases
Chemotherapy
Liver directed treatment
133 (15)
44 (5)
198 (22)
306 (34)
231 (25)
Line of therapy (as 
defined on individual 
trials)
First line
Second line
Third line or higher
Missing 
567 (62)
126 (14)
46 (5)
173 (19)
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2Table 2 Prognostic factors by univariable and multivariable analysis for progression free survival (PFS; data were not available for 
all variables, the maximum number of patients analysed for any variable was 873 for whom both PFS and OS data were available).
PFS Distribution 6-month PFS Rates
Univariable Multivariable Univariable Multivariable
Variable 
No 
patients
(n=873)
 HR (95% CI) P value Adjusted HR 
(95% CI)
P value OR  (95% CI) P value Adjusted OR 
(95% CI)
P value
ECOG 
performance 
    0
    ≥1
    Unknown
463
250
160
Ref
1.15 (0.96-1.38)
1.32 (0.98-1.79)
0.08
Ref
1.04 (0.92-
1.18)
1.41 (1.01-
1.98)
0.13
Ref
0.85 (0.58-
1.27)
0.47 (0.25-
0.91)
0.07
Ref
1.07 (0.71-1.62)
0.42 (0.21-0.84)
0.04
Age
   < 65 Years
   > 65 Years
540
333
Ref
1.10 (0.93-1.30)
0.28 Ref
0.80 (0.57-
1.11)
0.19
Sex
    Female 
    Male    
419
454
Ref 
1.22 (1.10-1.35)
<0.001 Ref 
1.26 (1.10-
1.45)
<0.001 Ref 
0.81 (0.59-
1.11)
0.20 Ref 
0.76 (0.55-1.06)
0.10
 LDH
    Normal
    
Elevated>ULN
    Unknown
330
386
157
Ref
1.66 (1.35-2.04)
0.98 (0.73-1.33)
<0.001
Ref
1.53 (1.29-
1.82)
0.97 (0.75-
1.26)
<0.001
Ref
0.33 (0.22-
0.49)
0.92 (0.55-
1.54)
<0.001
Ref
0.37 (0.24-0.56)
0.84 (0.47-1.51)
<0.001
ALP
    Normal
    
Elevated>ULN
    Unknown
428
162
283
Ref
1.91 (1.49-2.43)
1.06 (0.85-1.32)
<0.001
Ref
1.56 (1.25-
1.93)
<0.001
Ref
0.33 (0.19-
0.57)
<0.001
Ref
0.46 (0.26-0.82)
0.89 (0.50-1.60)
0.03
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30.98 (0.79-
1.21)
0.82 (0.48-
1.38)
Diameter of the 
largest liver 
metastasis
     < 3 cm 
> 3 cm
     Unknown
215
355
303
Ref
1.37 (1.13-1.66)
1.24 (0.90-1.69)
0.005
Ref
1.20 (1.03-
1.39)
1.10 (0.85-
1.44)
0.06
Ref
0.66 (0.43-
1.01)
0.87 (0.50-
1.51)
0.14
Ref
0.93 (0.59-1.46)
1.28 (0.72-2.28)
0.53
HR: hazard ratio, OR: odds ratio, ref: reference subgroup
Page 24 of 76Annals of Oncology
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4Table 3: Prognostic factors by univariable and multivariable analysis for overall survival (OS; data were not available for all 
variables, the maximum number of patients analysed for any variable was 912).
OS Distribution 1 Year OS Rates
Univariable Multivariable Univariate MultivariableVariable No. of Patients HR (95% CI) P 
value
Adjusted HR 
(95% CI)
P-
value
OR (95% CI) P-
value
Adjusted OR 
(95% CI)
P-
value
ECOG performance 
status
      0
      ≥1
   Unknown
475
250
187
Ref
1.49 (1.25-
1.78)
1.13 (0.85-
1.49)
<0.001
Ref
1.26 (1.11-
1.44)
1.04 (0.86-
1.26)
0.002
Ref
0.48 (0.34-
0.68)
0.76 (0.47-
1.23)
<0.001
Ref
0.69 (0.47-
1.01)
0.91 (0.56-
1.49)
0.16
Age
   < 65 Years
   > 65 Years
   Unknown
550
335
27
Ref
1.21 (1.02-
1.43)
1.59 (1.16-
2.17)
0.01
Ref
1.12 (0.97-
1.31)
1.76 (1.30-
2.38)
<0.001
Ref
0.66 (0.50-
0.89)
0.30 (0.09-
1.08)
0.01
Ref
0.68 (0.49-
0.93)
0.28 (0.09-
0.87)
0.01
 Sex
        Female
        Male
437
475
Ref
1.38 (1.18-
1.60)
<0.001 Ref
1.41 (1.16-
1.72)
<0.001 Ref 
0.60 (0.45-
0.79)
<0.001 Ref 
0.56 (0.41-
0.75)
<0.001
 LDH
    Normal
    Elevated>ULN
   Unknown
330
386
196
Ref
2.64 (2.11-
3.30)
1.89 (1.38-
2.59)
<0.001
Ref
2.31 (1.87-
2.87)
1.64 (1.13-
2.36)
<0.001
Ref
0.16 (0.11-
0.22)
0.34 (0.22-
0.52)
<0.001
Ref
0.19 (0.13-
0.28)
0.41 (0.27-
0.64)
<0.001
ALP
    Normal 428 Ref Ref Ref Ref
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5    Elevated>ULN
   Unknown
162
322
2.76 (2.27-
3.36)
1.37 (1.13-
1.67)
<0.001 1.98 (1.61-
2.42)
1.12 (0.90-
1.38)
<0.001 0.20 (0.12-
0.32)
0.68 (0.44-
1.04)
<0.001 0.36 (0.22-
0.59)
0.92 (0.62-
1.37)
<0.001
Diameter of the 
largest liver 
metastasis
         <3 cm          
         >3 cm
         Unknown
232
365
315
Ref
1.65 (1.41-
1.93)
1.34 (1.01-
1.78)
<0.001
Ref
1.26 (1.10-
1.45)
1.25 (0.97-
1.63)
0.002
Ref
0.42 (0.29-
0.60)
0.70 (0.44-
1.10)
<0.001
Ref
0.69 (0.46-
1.03)
0.91 (0.56-
1.46)
0.17
HR: hazard ratio, OR: odds ratio, ref: reference subgroup
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